Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Sep

Today In Oncology

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Related Videos

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC

High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT

Extended-Interval Dosing of Tarlatamab Found Safe Effective in SCLC

Favorable Safety Profile Found for Subcutaneous Tarlatamab in ES-SCLC

Genomic Profiles Compared in Early- and Average-Onset Metastatic Colorectal Cancer